<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4069">
  <stage>Registered</stage>
  <submitdate>5/02/2013</submitdate>
  <approvaldate>5/02/2013</approvaldate>
  <nctid>NCT01800695</nctid>
  <trial_identification>
    <studytitle>Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme</studytitle>
    <scientifictitle>A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-003884-23</secondaryid>
    <secondaryid>M12-356</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glioblastoma Multiforme</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-414
Treatment: drugs - Temozolomide
Treatment: other - Whole Brain Radiation

Experimental: Arm A - ABT-414 in combination with radiation and temozolomide

Experimental: Arm B - ABT-414 in combination with temozolomide

Experimental: Arm C - ABT-414 monotherapy


Treatment: drugs: ABT-414
ABT-414 will be administered by intravenous infusion

Treatment: drugs: Temozolomide
Temozolomide will be administered per label and local prescribing regulations.

Treatment: other: Whole Brain Radiation
Whole Brain radiation will be administered in 30 fractions.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number and percentage of participants with adverse events - Measurement by clinical lab results, vital signs, physical exam, and electrocardiogram (ECG)</outcome>
      <timepoint>Every week for an expected average of 34 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum concentration of ABT-414 - Measurement of the maximum concentration of ABT- 414 in the blood</outcome>
      <timepoint>Multiple time points in Cycles 1, 2, and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment, an expected average of 34 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Dose Limiting Toxicities - Measurement by clinical lab results, vital signs, physical exam, and electrocardiogram (ECG)</outcome>
      <timepoint>Every week for an expected average of 34 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Minimum Concentration of ABT-414 - Measurement of the minimum concentration of ABT-414 in the blood</outcome>
      <timepoint>Multiple time points in Cycles 1, 2, and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment, an expected average of 34 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Half-life of ABT-414 - Measurement of the clearance of ABT-414</outcome>
      <timepoint>Multiple time points in Cycles 1, 2, and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment, an expected average of 34 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Biomarker EGFR expression - Assessment of tumor biomarkers that may correlate with efficacy.</outcome>
      <timepoint>At screening and post-study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival - Progression Free Survival per RANO criteria is the length of time during and after the treatment of a disease, that the participant lives with the disease but does not get worse.</outcome>
      <timepoint>Multiple time points in each cycle, throughout study, and survival information monthly until 1 year after last visit, or the participant becomes lost to follow up, or study termination.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - The overall response rate will be evaluated every 8 weeks at each assessment of disease according to RANO criteria, up to 28 months</outcome>
      <timepoint>Multiple time points in each cycle, throughout study, and survival information monthly until 1 year after last visit, or participant becomes lost to follow up, or study termination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Glioblastoma Multiforme (GBM)

          2. 70 or above on Karnofsky Performance Status

          3. Adequate bone marrow function

          4. Recurrent GBM per RANO criteria

          5. Subjects must have confirmed EGFR amplification by central lab</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. For Subjects with recurrent GBM in Arm B, subject has received prior treatment with
             bevacizumab, nitrosourea, or has secondary GBM

          2. For Subjects with recurrent GBM in Arm C, subject has received prior treatment with
             bevacizumab, or has secondary GBM

          3. Allergies to temozolomide, dacarbazine, IgG containing agents

          4. Anti-cancer treatment 28 days prior to study Day 1, except in Arm B expanded cohort
             temozolomide therapy is allowed

          5. Subjects that have had more than one disease recurrence</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>2/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>202</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>19/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Brisbane and Womens Hospital /ID# 133368 - Brisbane</hospital>
    <hospital>Chris O'Brien Lifehouse /ID# 133028 - Camperdown</hospital>
    <hospital>Austin Hospital /ID# 90833 - Heidelberg</hospital>
    <hospital>Royal North Shore Hospital /ID# 132912 - St. Leonards</hospital>
    <hospital>Westmead Hospital /ID# 136172 - Westmead</hospital>
    <postcode>4029 - Brisbane</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with
      glioblastoma multiforme.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01800695</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Earle Bain, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>